GlycoNoVi Understanding the Role of Glycans in Human Norovirus Infection: a Key to Unlock New Therapies
- Coordinator
- Universita Degli Studi Di Firenze, Italy
- Runs
- 1 January 2023 to 30 June 2027
- Status
- Running
- EU funding
- €2.4m
- Total cost
- —
- Partners
- 16 organisations in 8 countries
- Type
- Marie Skłodowska-Curie Action
- Grant agreement
- 101072717
What the project is doing
In the project's own words, from its summary on CORDIS.
Glycans are carbohydrate structures ubiquitously found on the surface of cells and take part in many biological processes, including cell signaling and neoplasia. Research on glycans is challenging in part due to the limited availability of biologically relevant synthetic glycans and to technical challenges in the analysis of glycan-protein interactions. Glycans also exhibit key roles in viral infections, mediating virus attachment and entry.
Human noroviruses (NoVs) are the major cause of viral gastroenteritis and foodborne illnesses causing morbidity, mortality and economic losses. NoV infections are self-limiting in healthy individuals but are associated with severe complications in immunocompromised individuals, the elderly and young children. In addition, frequently occurring new NoV genotypes and variants can cause large outbreaks and epidemics worldwide.
Very little is known about NoV infections in most non-human hosts and the close genetic similarities between some animal and human NoVs leads to the realistic hypothesis that the virus might jump the species barrier triggering pandemic variants. Importantly, no therapy is currently available to treat or prevent NoV infections. The requirement for NoVs to attach to specific glycans to infect hosts’ tissues, and cells, has been well established but the underlying mechanisms remain to be elucidated.
Going beyond the state-of-the-art, the overall aims of GlycoNoVi is training 9 researchers to address knowledge gaps on NoV glycan interactions and investigate the exciting possibility of developing synthetic glycans as antiviral strategies to treat NoV infection. These aims will be achieved bringing together 5 academic and 3 industrial leaders in glycoscience, glycovirology and NoV field and relying on a multidisciplinary and interconnected approach which is declinate in research-oriented WP1-5 and WP6-8 focused respectively on training, outreach and coordination.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universita Degli Studi Di Firenze | Florence | Italy | Coordinator |
| Inbiose | Zwijnaarde | Belgium | Participant |
| Universiteit Gent | Gent | Belgium | Associatedpartner |
| Universitaet Zu Luebeck | Lubeck | Germany | Participant |
| Danmarks Tekniske Universitet | Kongens Lyngby | Denmark | Associatedpartner |
| Glycom AS | Horsholm | Denmark | Participant |
| Agencia Estatal Consejo Superior De Investigaciones Cientificas | Madrid | Spain | Participant |
| Universidad De Sevilla | Sevilla | Spain | Associatedpartner |
| Centre National De La Recherche Scientifique CNRS | Paris | France | Participant |
| Universite Grenoble Alpes | Grenoble | France | Associatedpartner |
| React4life SpA | Genova | Italy | Participant |
| Universita' Degli Studi Di Milano-Bicocca | Milano | Italy | Associatedpartner |
| Erasmus Universitair Medisch Centrum Rotterdam | Rotterdam | Netherlands | Participant |
| Iceni Glycoscience Limited | Colchester | United Kingdom | Associatedpartner |
| The University of Manchester | Manchester | United Kingdom | Associatedpartner |
| University of East Anglia | Norwich | United Kingdom | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI